DURECT Competitors

DURECT (NASDAQ:DRRX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Risk & Volatility

DURECT has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Profitability

This table compares DURECT and Heron Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

52.2% of DURECT shares are held by institutional investors. Comparatively, 88.9% of Heron Therapeutics shares are held by institutional investors. 5.2% of DURECT shares are held by company insiders. Comparatively, 4.6% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for DURECT and Heron Therapeutics, as provided by MarketBeat.com.

DURECT currently has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Heron Therapeutics has a consensus target price of $28.6667, suggesting a potential upside of 120.34%. Given DURECT's higher probable upside, analysts clearly believe DURECT is more favorable than Heron Therapeutics.

Valuation and Earnings

This table compares DURECT and Heron Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

DURECT has higher earnings, but lower revenue than Heron Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

DURECT beats Heron Therapeutics on 9 of the 13 factors compared between the two stocks.

DURECT (NASDAQ:DRRX) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Valuation & Earnings

This table compares DURECT and Applied Molecular Transport's gross revenue, earnings per share (EPS) and valuation.

DURECT has higher revenue and earnings than Applied Molecular Transport. DURECT is trading at a lower price-to-earnings ratio than Applied Molecular Transport, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.2% of DURECT shares are owned by institutional investors. Comparatively, 63.4% of Applied Molecular Transport shares are owned by institutional investors. 5.2% of DURECT shares are owned by insiders. Comparatively, 26.7% of Applied Molecular Transport shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares DURECT and Applied Molecular Transport's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for DURECT and Applied Molecular Transport, as provided by MarketBeat.

DURECT presently has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Applied Molecular Transport has a consensus target price of $80.3333, suggesting a potential upside of 135.10%. Given DURECT's higher probable upside, equities analysts clearly believe DURECT is more favorable than Applied Molecular Transport.

Summary

DURECT beats Applied Molecular Transport on 7 of the 11 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares Zealand Pharma A/S and DURECT's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Zealand Pharma A/S and DURECT's gross revenue, earnings per share and valuation.

DURECT has lower revenue, but higher earnings than Zealand Pharma A/S. DURECT is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.5% of Zealand Pharma A/S shares are held by institutional investors. Comparatively, 52.2% of DURECT shares are held by institutional investors. 5.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zealand Pharma A/S and DURECT, as provided by MarketBeat.

Zealand Pharma A/S currently has a consensus target price of $43.00, indicating a potential upside of 45.07%. DURECT has a consensus target price of $7.00, indicating a potential upside of 382.76%. Given DURECT's higher possible upside, analysts clearly believe DURECT is more favorable than Zealand Pharma A/S.

Volatility & Risk

Zealand Pharma A/S has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Summary

DURECT beats Zealand Pharma A/S on 10 of the 13 factors compared between the two stocks.

DURECT (NASDAQ:DRRX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

52.2% of DURECT shares are owned by institutional investors. Comparatively, 93.1% of Arcutis Biotherapeutics shares are owned by institutional investors. 5.2% of DURECT shares are owned by company insiders. Comparatively, 39.0% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for DURECT and Arcutis Biotherapeutics, as provided by MarketBeat.com.

DURECT currently has a consensus price target of $7.00, suggesting a potential upside of 382.76%. Arcutis Biotherapeutics has a consensus price target of $54.40, suggesting a potential upside of 119.53%. Given DURECT's higher probable upside, research analysts plainly believe DURECT is more favorable than Arcutis Biotherapeutics.

Profitability

This table compares DURECT and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares DURECT and Arcutis Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation.

DURECT has higher revenue and earnings than Arcutis Biotherapeutics. DURECT is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

DURECT has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Summary

DURECT beats Arcutis Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Earnings and Valuation

This table compares Repare Therapeutics and DURECT's top-line revenue, earnings per share (EPS) and valuation.

DURECT has higher revenue and earnings than Repare Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.3% of Repare Therapeutics shares are held by institutional investors. Comparatively, 52.2% of DURECT shares are held by institutional investors. 33.6% of Repare Therapeutics shares are held by insiders. Comparatively, 5.2% of DURECT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Repare Therapeutics and DURECT's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Repare Therapeutics and DURECT, as provided by MarketBeat.com.

Repare Therapeutics presently has a consensus target price of $45.00, suggesting a potential upside of 35.62%. DURECT has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Given DURECT's higher probable upside, analysts plainly believe DURECT is more favorable than Repare Therapeutics.

Summary

Repare Therapeutics beats DURECT on 8 of the 14 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Volatility and Risk

Kura Oncology has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Kura Oncology and DURECT, as provided by MarketBeat.

Kura Oncology presently has a consensus target price of $42.5556, suggesting a potential upside of 128.42%. DURECT has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Given DURECT's stronger consensus rating and higher possible upside, analysts clearly believe DURECT is more favorable than Kura Oncology.

Earnings & Valuation

This table compares Kura Oncology and DURECT's top-line revenue, earnings per share and valuation.

DURECT has higher revenue and earnings than Kura Oncology. DURECT is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kura Oncology and DURECT's net margins, return on equity and return on assets.

Insider and Institutional Ownership

52.2% of DURECT shares are owned by institutional investors. 4.9% of Kura Oncology shares are owned by insiders. Comparatively, 5.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

DURECT beats Kura Oncology on 8 of the 13 factors compared between the two stocks.